PDF下载 ( 2017 KB)
SCIE收录的胃肠肝病学期刊发表的中国内地作者的肝脏疾病研究文献计量分析
DOI: 10.3969/j.issn.1001-5256.2022.04.024
利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明：赵天业、易嘉欣、吕海永参与了研究数据的获取分析解释过程；牛俊奇、姜晶对研究的思路和设计有关键贡献；吴燕华、潘禹辰参与起草与修改文章关键内容。
A bibliometric analysis of liver disease research articles published by Chinese mainland authors in Gastroenterology & Hepatology journals indexed in Science Citation Index Expanded
-
摘要:
目的 检索2016年—2020年中国(不含港澳台地区)作者在SCIE(Science Citation Index Expanded)数据库收录的胃肠肝病学期刊上发表的肝脏疾病相关论文，对其题录与引文数据进行统计分析，以了解中国学者在肝脏疾病研究领域的贡献及其影响力。 方法 文献计量学分析数据来源于SCIE数据库与JCR(Journal Citation Report)。在SCIE数据库中检索出版年为2016年—2020年发表在JCR胃肠肝病学期刊上，题名或摘要中包含Liver、Hepatocellular、Hepatitis、Cirrhosis或Hepatic，出版物类型为Article的期刊文章，排除临床指南，并筛选通信作者单位含有中国(不含港澳台地区)机构的记录。使用R package bibliometrix计算纳入文献在2016年—2020年被中国作者和全球作者在胃肠肝病学期刊发表的肝脏疾病研究引用的频次。使用R package DescTools对构成比的变化进行Cochran-Armitage趋势检验。 结果 2016年—2020年Q1区胃肠肝病学期刊上，中国作者发表的肝脏疾病研究占比为9.5%。近年，中国作者在高水平胃肠肝病学期刊(Q1区)上发表的肝脏疾病研究数量不断增加，占全球研究的比例从6.0%不断上升至12.2%(P＜0.001)。中国作者在Q1区胃肠肝病学期刊发表的肝脏疾病研究获国自然基金资助的比例达79.7%，5年间，各分区胃肠肝病学期刊上发表的中国作者的研究获国自然基金资助的比例均无明显变化。比较被中国与全球作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次，显示了中国作者发表的在国内和国际学界均具有较高影响的肝脏疾病研究。 结论 近年，中国作者在SCIE收录、高影响力的胃肠肝病学期刊发表的肝脏疾病研究数量不断增加，其中大部分研究获国自然基金资助。中国学者在胃肠肝病学期刊上发表的肝脏疾病论文被国内学界和国际学界广泛认可。 Abstract:Objective To investigate the articles on liver diseases published by authors from China (excluding Hong Kong, Macao, and Taiwan regions) in Gastroenterology & Hepatology journals indexed in Science Citation Index Expanded (SCIE) in 2016-2020, to analyze the bibliographic and citation data of these articles, and to understand the contribution and impact of Chinese scholars in the field of liver disease research in recent years. Methods The data for bibliometric analysis came from the SCIE database and Journal Citation Reports (JCR). The SCIE database was searched for the journal articles published in JCR Gastroenterology & Hepatology journals in 2016-2020, with a title or abstract containing "Liver", "Hepatocellular", "Hepatitis", "Cirrhosis", or "Hepatic" and a publication type of Article. Clinical guidelines were excluded, and the records with the corresponding author's affiliation containing institutions in China (excluding Hong Kong, Macao, and Taiwan regions) were screened out. R package bibliometrix was used to calculate the frequency of citations of included articles by liver disease studies published by Chinese and global authors in the Gastroenterology & Hepatology journals in 2016-2020, and R package DescTools was used to perform the Cochran-Armitage trend test to observe the change in composition ratio. Results In the Q1 Gastroenterology & Hepatology journals in 2016-2020, liver disease studies published by Chinese authors accounted for 9.5%. In recent years, the proportion of liver disease studies published by Chinese authors in Q1 Gastroenterology & Hepatology journals continues to increase from 6.0% to 12.2% (P < 0.001). Among the liver disease studies published by Chinese authors in Q1 Gastroenterology & Hepatology journals, 79.7% were funded by National Natural Science Foundation of China, and there was no significant change in the proportion of studies funded by National Natural Science Foundation of China and published by Chinese authors in each partition of Gastroenterology & Hepatology journals in 2016-2020. The frequency of citations of included articles by liver disease studies published by Chinese and global authors in the Gastroenterology & Hepatology journals showed that liver disease studies published by Chinese authors had a high impact in both domestic and international academic communities. Conclusion In recent years, there has been a constant increase in the number of liver disease studies published by Chinese authors in high-impact Gastroenterology & Hepatology journals indexed in SCIE, and most of these studies have been funded by National Natural Science Foundation of China. The liver disease studies published by Chinese authors in Gastroenterology & Hepatology journals have been widely recognized by domestic and international academic communities. -
Key words:
- Liver Diseases /
- Bibliometrics /
- Gastroenterology /
- Databases, Bibliographic /
- Bibliography of Medicine
-
注：TC，总被引频次；LC，被中国作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次；GC, 被全球作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次；图中省略了被引频次＞50的点。
图 1 2016年—2020年中国作者在Q1区胃肠肝病学期刊发表肝脏疾病研究被引频次分布
Figure 1. The distribution of citation frequency of Chinese authors' published liver diseases research in Q1 Gastroenterology and Hepatology journals during 2016 to 2020
表 1 2016年—2020年在SCIE收录的胃肠肝病学期刊上发表的肝脏疾病研究特征
Table 1. Characteristics of liver diseases research published on Gastroenterology & Hepatology journals indexed in SCIE during 2016 to 2020
项目 中国作者发文数量(篇) 全球作者发文数量(篇) 中国作者发文占比(%) 出版年 2016 446 3294 13.5 2017 464 3324 14.0 2018 474 3259 14.5 2019 640 3618 17.7 2020 681 3596 18.9 期刊JCR分区 Q1 473 4961 9.5 Q2 984 5666 17.4 Q3 799 3413 23.4 Q4 449 3051 14.7 开放获取 1283 8630 14.9 被引频次 0 302 1447 20.9 1~5 1066 5840 18.3 6~10 514 3187 16.1 11~20 464 3142 14.8 ＞20 359 3485 10.3 
下载: 导出CSV
表 2 2016年—2020年中国作者在2020年Q1区胃肠肝病学期刊发表肝脏疾病研究情况
Table 2. Chinese authors published liver diseases research on Gastroenterology & Hepatology journals in the Q1 of 2020 during 2016-2020
序号 期刊 中国作者发文数量(篇) 全球作者发文数量(篇) 中国作者发文占比(%) 1 Hepatology 226 1382 16.4 2 Journal of Hepatology 97 918 10.6 3 Alimentary Pharmacology & Therapeutics 21 390 5.4 4 Gastroenterology 20 365 5.5 5 Clinical Gastroenterology and Hepatology 11 296 3.7 6 Gut 38 270 14.1 7 Clinics in Liver Disease 0 215 0 8 Journal of Gastroenterology 5 183 2.7 9 American Journal of Gastroenterology 8 178 4.5 10 Journal of Hepato-Biliary-Pancreatic Sciences 6 151 4.0 11 Liver Cancer 8 121 6.6 12 Clinical and Molecular Hepatology 3 100 3.0 13 Lancet Gastroenterology & Hepatology 6 89 6.7 14 Hepatobiliary Surgery and Nutrition 8 75 10.7 15 Cellular and Molecular Gastroenterology and Hepatology 4 60 6.7 16 Gastrointestinal Endoscopy 0 48 0 17 Gut Microbes 5 32 15.6 18 Gastric Cancer 5 31 16.1 19 Endoscopy 1 24 4.2 20 Digestive Endoscopy 0 19 0 21 Journal of Crohn’s & Colitis 1 9 11.1 22 Nature Reviews Gastroenterology & Hepatology 0 5 0 23 Seminars in Liver Disease 0 0 -
下载: 导出CSV
表 3 2016年—2020年中国作者在SCIE收录的不同分区胃肠肝病学期刊上发表的肝脏疾病研究占全球同分区胃肠肝病学期刊上发表的肝脏疾病研究比例变化
Table 3. The proportion of liver disease research published by Chinese authors in different divisions of Gastroenterology & Hepatology journals indexed in SCIE accounted for the change in the proportion of liver diseases research published in the same division in the world during 2016 to 2020
项目 2016年 2017年 2018年 2019年 2020年 Z值 P值 Q1区(中国/全球) 6.0%(58/961) 8.0%(77/961) 9.6%(95/987) 11.5%(121/1052) 12.2%(122/1000) -0.05 ＜0.0011) Q2区(中国/全球) 16.7%(193/1154) 17.6%(196/1112) 14.3%(153/1069) 19.2%(232/1210) 18.7%(210/1121) -1.59 0.056 Q3区(中国/全球) 19.9%(111/559) 22.5%(137/610) 23.6%(148/626) 25.6%(195/761) 24.3%(208/857) -2.20 0.0141) Q4区(中国/全球) 13.5%(84/620) 8.4%(54/641) 13.5%(78/577) 15.5%(92/595) 22.8%(141/618) -5.72 ＜0.0011) 注：1)P＜0.025。
下载: 导出CSV
表 4 2016年—2020年中国作者在SCIE收录的胃肠肝病学期刊上发表的肝脏疾病研究获国家自然科学基金资助情况
Table 4. The research on liver diseases published by Chinese authors in the Gastroenterology & Hepatology journals indexed in SCIE was funded by the National Natural Science Foundation of China during 2016 to 2020
项目 2016年 2017年 2018年 2019年 2020年 Z值 P值 Q1区(资助/全部) 81.0%(47/58) 76.6%(59/77) 91.6%(87/95) 80.2%(97/121) 71.3%(87/122) 1.62 0.0521) Q2区(资助/全部) 46.1%(89/193) 49.5%(97/196) 53.6%(82/153) 52.6%(122/232) 53.8%(113/210) -1.65 0.0491) Q3区(资助/全部) 52.3%(58/111) 39.4%(54/137) 49.3%(73/148) 49.2%(96/195) 40.9%(85/208) 1.00 0.159 Q4区(资助/全部) 35.7%(30/84) 46.3%(25/54) 32.1%(25/78) 35.9%(33/92) 38.3%(54/141) 0.04 0.4861) 注：1)为对下降趋势进行的检验。
下载: 导出CSV
表 5 2016年—2020年中国作者在SCIE收录的胃肠肝病学期刊上发表的肝脏疾病研究被中国作者与全球作者在胃肠肝病学期刊上发表的肝脏疾病研究引用频次排名前9的研究
Table 5. The liver disease research published by Chinese authors in the Gastroenterology & Hepatology journals indexed in SCIE was the 9 most frequently cited studies of liver disease research published by Chinese authors and global authors in the Gastroenterology & Hepatology journals during 2016 to 2020
题名 期刊 出版年 通信作者单位 TC(排名) GC(排名) LC(排名) Development of Diagnostic Criteria and A Prognostic Score for Hepatitis B Virus-Related Acute- On-Chronic Liver Failure GUT 2018 浙江大学医学院附属第一医院 74(54) 20(6) 20(1) Serum Hepatitis B Virus RNA is Encapsidated Pregenome RNA that may be Associated with Persistence of Viral Infection and Rebound J HEPATOL 2016 北京大学 191(13) 45(1) 19(2) New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment HEPATOLOGY 2017 首都医科大学附属北京友谊医院 59(76) 18(7) 13(3) Covered Tips Versus Endoscopic Band Ligation Plus Propranolol for The Prevention of Variceal Rebleeding in Cirrhotic Patients with Portal Vein Thrombosis: A Randomised Controlled Trial GUT 2018 空军军医大学西京医院 50(103) 16(9) 11(4) Targeting Hepatic Traf1-Ask1 Signaling to Improve Inflammation, Insulin Resistance, And Hepatic Steatosis J HEPATOL 2016 武汉大学 73(58) 14(12) 11(4) Liver Transplantation for Hepatocellular Carcinoma Beyond the Milan Criteria GUT 2016 浙江大学医学院附属第一医院 95(40) 21(5) 10(6) Targeting Traf3 Signaling Protects Against Hepatic Ischemia/Reperfusions Injury J HEPATOL 2016 武汉大学 59(76) 10(21) 10(6) Perioperative Blood Transfusion Does Not Influence Recurrence-Free and Overall Survivals After Curative Resection for Hepatocellular Carcinoma A Propensity Score Matching Analysis J HEPATOL 2016 海军军医大学附属东方肝胆外科医院 69(60) 13(15) 9(8) Circular RNA Circmto1 Acts as The Sponge of Microrna-9 To Suppress Hepatocellular Carcinoma Progression HEPATOLOGY 2017 浙江大学，海军军医大学 664(1) 10(22) 9(8) Eight Millimetre Covered Tips Does Not Compromise Shunt Function but Reduces Hepatic Encephalopathy in Preventing Variceal Rebleeding J HEPATOL 2017 空军军医大学西京医院 56(86) 22(4) 8(10) …… …… …… …… …… …… …… Comparison of Laboratory Tests, Ultrasound, or Magnetic Resonance Elastography to Detect Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis HEPATOLOGY 2017 华中科技大学同济医学院附属协和医院 238(9) 45(1) 7(12) …… …… …… …… …… …… …… COVID-19: Abnormal Liver Function Tests J HEPATOL 2020 南方科技大学第二附属医院 242(8) 26(3) 5(22) Clinical Features of COVID-19-Related Liver Functional Abnormality CLIN GASTROENTEROL HEPATOL 2020 复旦大学附属公共卫生临床中心 236(10) 17(8) 5(23) 注：J HEPATOL，Journal of Hepatology；CLIN GASTROENTEROL HEPATOL，Clinical Gastroenterology and Hepatology。
下载: 导出CSV
-
[1] MAYO CLINIC STAFF. Liver disease[OL]. (2020-2-21)[2021-7-31]. https://www.mayoclinic.org/diseases-conditions/liver-problems/symptoms-causes/syc-20374502. [2] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019. [3] ELLEGAARD O, WALLIN JA. The bibliometric analysis of scholarly production: How great is the impact?[J]. Scientometrics, 2015, 105(3): 1809-1831. DOI: 10.1007/s11192-015-1645-z. [4] YANG HY, WANG D, CHEN C, et al. Global research status of gastroenterology and hepatology: A bibliometrics study[J]. Medicine (Baltimore), 2021, 100(15): e25291. DOI: 10.1097/MD.0000000000025291. [5] HU SK, HUANG J, HONG WD, et al. The 50 most-cited articles in gastroenterology and hepatology from Mainland China[J]. Pak J Med Sci, 2017, 33(1): 215-220. DOI: 10.12669/pjms.331.12286. [6] MA HY, AO YK, LIU WB, et al. A bibliometric analysis on cohort study of liver cancer in China[J]. Chin J Epidemiol, 2020, 41(1): 115-119. DOI: 10.3760/cma.j.issn.0254-6450.2020.01.021.马宏宇, 敖杨坤, 刘文斌, 等. 中国肝癌相关队列研究的文献计量分析[J]. 中华流行病学杂志, 2020, 41(1): 115-119. DOI: 10.3760/cma.j.issn.0254-6450.2020.01.021. [7] LI G, LIN J, JIANG C, et al. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: A bibliometric and visual analysis[J]. J Int Med Res, 2020, 48(4): 300060519893234. DOI: 10.1177/0300060519893234. [8] XU G, JIN B, XIAN X, et al. Evolutions in the management of hepatocellular carcinoma over last 4 decades: An analysis from the 100 most influential articles in the field[J]. Liver Cancer, 2021, 10(2): 137-150. DOI: 10.1159/000513412. [9] HU AGZ. Public funding and the ascent of Chinese science: Evidence from the National Natural Science Foundation of China[J]. Research Policy, 2020, 49(5): 13. DOI: 10.1016/j.respol.2020.103983. [10] LIU Y, GAO Z, WANG H, et al. Analysis of projects funded by the National Natural Science Foundation of China during the years of 2014-2018[J]. Ann Transl Med, 2019, 7(12): 267. DOI: 10.21037/atm.2019.05.63. [11] R CORE TEAM. R: A language and environment for statistical computing[OL]. https://www.R-project.org/. [12] ARIA M, CUCCURULLO C. bibliometrix: An R-tool for comprehensive science mapping analysis[J]. J Informetr, 2017, 11(4): 959-975. DOI: 10.1016/j.joi.2017.08.007. [13] SIGNORELL A. DescTools: Tools for descriptive statistics[OL]. https://cran.r-project.org/package=DescTools. [14] NESHAT SY, QUIROZ VM, WANG Y, et al. Liver disease: Induction, progression, immunological mechanisms, and therapeutic interventions[J]. Int J Mol Sci, 2021, 22(13): 6777. DOI: 10.3390/ijms22136777. [15] IOANNOU GN, GREEN PK, BERRY K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma[J]. J Hepatol, 2018, 68(1): 25-32. DOI: 10.1016/j.jhep.2017.08.030. [16] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. [17] BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-6736(16)32453-9. [18] LOOMBA R, ADAMS LA. Advances in non-invasive assessment of hepatic fibrosis[J]. Gut, 2020, 69(7): 1343-1352. DOI: 10.1136/gutjnl-2018-317593. [19] RUDIGER MS, ANTONS D, SALGE TO. The explanatory power of citations: A new approach to unpacking impact in science[J]. Scientometrics, 2021, 126: 9779-9809. DOI: 10.1007/s11192-021-04103-w. [20] ZHU HR. Home country bias in academic publishing: A case study of the New England Journal of Medicine[J]. Learned Publishing, 2021, 34(4): 578-584. DOI: 10.1002/leap.1404. [21] WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710. DOI: 10.1016/j.jhep.2016.05.029. [22] XU X, LU D, LING Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6): 1035-1041. DOI: 10.1136/gutjnl-2014-308513. [23] SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009. [24] LV Y, QI X, HE C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. DOI: 10.1136/gutjnl-2017-314634. 期刊类型引用(5)
1. 张效收，李红专，李晶，史恒蔚，李彦强，张永健，刘跃振，赵建栋. 基于“肝藏血主疏泄”理论探讨肝及肝脏疾病与绝经后骨质疏松的关系. 现代中医药. 2024(01): 32-36 . 
百度学术2. 何秋霞，纪汉斌，禹文海，魏大巧，黄芬. 雌、孕激素与病毒感染的关系. 中国人兽共患病学报. 2019(03): 258-262+270 . 百度学术3. 王建红，任毅，尹建红，杨静. 高泌乳素血症临床诊断新进展. 中国实用神经疾病杂志. 2018(02): 230-232 . 百度学术4. 李秀兰，刘青，王夫川，王明，马晓鹏. 诺舒阻抗控制子宫内膜去除术治疗肝病患者异常子宫出血的远期疗效. 肝脏. 2018(07): 596-599 . 百度学术5. 李秀兰，刘青，冉冉，张华. 473例肝病患者异常子宫出血的病因分析. 北京医学. 2017(09): 924-927 . 百度学术其他类型引用(2)
-
百度学术
